180 results about "Cardiac dysfunction" patented technology

The above-described methods and apparatus are believed to be of particular benefit for patients suffering heart failure including cardiac dysfunction, chronic HF, and the like and all variants as described herein and including those known to those of skill in the art to which the invention is directed. It will understood that the present invention offers the possibility of monitoring and therapy of a wide variety of acute and chronic cardiac dysfunctions. The current invention provides systems and methods for delivering therapy for cardiac hemodynamic dysfunction.

A plethysmogram signal is sensed from a patient and provided to a programmer device for monitoring the condition of the patient and for optimizing pacing parameters of a cardiac device implanted in the patient. The programmer device analyzes the plethysmogram signal for cardiac performance associated with different pacing parameters. The cardiac performance is indicated by, for example, a pulse amplitude response, a degree of pulsus alternans, or irregularity in the pressure pulses detected in an atrial fibrillation patient. The pacing parameters resulting in the best cardiac performance are selected as the optimum pacing parameters. In one embodiment, the programmer device monitors a Valsalva maneuver performed by a patient. Optimum pacing parameters are derived by analysis of the plethysmogram signals obtained during performance of the Valsalva maneuver while the patient is paced using different pacing parameters.

Disclosed are antisense oligonucleotide, polynucleotide, and peptide nucleic acid compounds that specifically bind to mammalian mRNA encoding a beta1-adrenoceptor polypeptide and that are useful in the control and/or treatment of cardiac dysfunction, hypertension, hypertrophy, myocardial ischemia, and other cardiovascular diseases in an affected mammal, and preferably, in a human subject. The antisense compounds disclosed herein, and pharmaceutical formulations thereof, provide sustained control of beta1-adrenoceptor expression over prolonged periods, and achieve therapeutic effects from as little as a single dose. Administration of these antisense compositions to approved animal models resulted in a decrease in blood pressure, but no significant change in heart rate. Use of such antisense compositions in the reduction of beta1-adrenoceptor polypeptides in a host cell expressing beta1-adrenoceptor-specific mRNA, and in the preparation of medicaments for treating human and animal diseases, and in particular, hypertension and other cardiac dysfunction is also disclosed.

Methods, systems, and apparatus for the treatment of heart failure (both systolic and diastolic), hypertension, and arrhythmia in patients by stimulating one or more nerves, particularly peripheral nerves, using neurostimulation are described. The therapeutic treatment is accomplished by applying electrical signals to at least one or more nerves using cutaneous, subcutaneous, implantable, or catheter-based neurostimulation assemblies, alone or in combination with one or more additional therapy or stimulation devices associated with the patient's heart, and/or with one or more therapeutic drug infusions or therapies, such as immune modulation therapy (IMT).

The present invention relates to the secure delivery of an extra-systolic stimulation (ESS) therapy to treat cardiac dysfunction that employs atrial and/or ventricular extra-systoles via pacing-like stimulation of the heart. These extra-systoles must be timed correctly to achieve beneficial effects on myocardial mechanics (benefit) while maintaining an extremely low level of risk of arrhythmia induction and excellent ICD-like arrhythmia sensing and detection (security). Further experience with ESS has led to improved implementation methods that depend on better blanking, ESS stimulation timing (of an “extra-systolic interval” or ESI), and ESS therapy delivery options and guidance. These methods may be employed individually or in combinations in an external or implantable ESS therapy delivery device.

The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.

The invention relates to a medical coating layer coated on the gasbag surface of a balloon pipe which can release the narrowing of blood vessel and reduce free radical damage after operation, belonging to the field of the medical instruments, which comprises 1% to 99% of medicine and 1% to 99% of medical carrier, wherein the medical comprises a single oxidation resisting medicine, or a mixture of a plurality of oxidation resisting medicines, or a mixture of a single or a plurality of oxidation resisting medicines with blood vessel narrowing resisting medicines; the medicines are evenly coated on the surface of the gasbag all together or layer by layer. The medical coating layer coated on the gasbag surface of a balloon pipe has the advantages that through local medication the damage to human cells and organizations after blood transfusion due to myocardial ischemia can be effectively released and reduced and the cardiac dysfunction can be finally cured.

Methods to identify and risk stratify disease states, cardiac structural defects, functional cardiac deficiencies induced by teratogens and other toxic agents, pathological substrates, conduction delays and defects, and ejection fraction using single channel biological data obtained from the subject. A modified Matching Pursuit (MP) algorithm may be used to find a noiseless model of the data that is sparse and does not assume periodicity of the signal. After the model is derived, various metrics and subspaces are extracted to characterize the cardiac system. In another method, space-time domain is divided into a number of regions (which is largely determined by the signal length), the density of the signal is computed in each region and input to a learning algorithm to associate them to the desired cardiac dysfunction indicator target.

Pulsatile flow in synchronization with the systole and diastole of a patient's own pulse is generated during auxiliary circulation therapy administered to a patient under cardiac dysfunction. As a result, the diastole augmentation function is maintained, blood flow to the coronary artery is increased, and the therapeutic effect of intending to restore cardiac function without applying after-loading to the heart is improved.

Pulsatile flow generation control device Y incorporated in a pulsation-type auxiliary circulation system (X) as an apparatus system having an electromagnetic valve 7 in blood supply lines (4, 6, 8) on the delivery side of artificial lung 5 and a control means 11 for performing control-output relating to the opening and closing operation of the electromagnetic valve 7. The control means 11 has at least a delay circuit and is such that the electromagnetic valve 7 is actuated to close and is maintained closed for a predetermined time interval based on delay detection and is actuated to open based on delay cancellation so that blood flow is periodically interrupted.

The present invention is directed to a pharmaceutical composition, and methods of use thereof, comprising at least one agent which target multiple adenosine receptors (AR) simultaneously in a stoichiometric relationship (i.e. each AR receptor is targeted to an equal extent). Aspects of the present invention relate to pharmaceutical compositions, and uses thereof, comprising at least one agent which co-activates an A₁-adenosine receptor (A₁-AR) and an A_2A-adenosine receptor (A_2A-AR) or a combination of at least one agent which activates an A₁-AR and at least one agent which activates an A_2A-AR, where both the A₁-AR and A_2A-AR are activated in a stoichiometric relationship such that the level of biological activation of A₁-AR is approximately the same level of biological activation of A_2A-AR. Other aspects of the present invention relates to methods for the therapeutic and prophylactic treatment of cardiac dysfunction in a subject having or at risk of having a cardiac dysfunction, for example, but not limited to, for the treatment of a subject with myocardial infarction, such as acute myocardial infarction, coronary ischemia or congestive heart failure and other cardiac dysfunctions.

The invention discloses tea paste with a myocardial ischemia function improving function and a preparation method of the tea paste. The tea paste is prepared from the following ingredients in parts by weight: 200 to 350 parts of Puer tea, 300 to 500 parts of fresh burdock, 300 to 500 parts of fresh yam, 50 to 100 parts of Chinese date and 40 to 60 parts of astragalus. The tea paste has the advantages that the extraction process is simple, the extraction efficiency is high, the energy consumption and the loss are little, the cost is low, and the special curative effect can be realized on chronic hypertension, hepatosis and cardiac dysfunction after the tea paste is eaten for a long time.

Described herein are inventions is directed to methods of treating a cardiac dysfunction and symptoms of cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. The probenecid may be administered in at least one of an injection, orally, or transdermally. The amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum BNP levels, a normalization of serum sodium concentrations, and combinations thereof In an embodiment, probenecid is administered over a period of about 8 hours to about 24 hours. Probenecid may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Probenecid may be administered in an amount sufficient to treat the symptoms of cardiac dysfunction.

The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to neukinase. In other aspects, the present invention further provides methods of identifying predisposition to cardiac dysfunction, methods of detecting the presence of neukinase, neukinase nucleic acid, methods of screening for agents which affect neukinase activity, and methods of modulating neukinase activity.